Global High Potency API CDMOs Market OverviewThe global High Potency API CDMOs market is projected to achieve strong single-digit growth by 2027, driven by a rapid surge in demand for oncology ...

Shifting gears, it turns out that 2025 was a slightly off year for drug approvals by the US Food and Drug Administration. A ...

Five undervalued stocks including CleanSpark, Sanofi, Uber, Macy's and e.l.f. Beauty combine discounted valuations with strong analyst buy ratings for 2026.

Jollibee Foods Corp plans to spin off its international operations and list the new unit as an independent company on a U.S.

Enable Injections closed a $215 million Series C financing in January 2022 led by Magnetar Capital, including Sanofi and multiple additional new institutional investors. Enable received significant ...

Jollibee Foods Corp. announces plans to spin off its international operations for a U.S. listing by 2027 while maintaining ...

Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration to expand its use to children aged one year and older with stage 2 type 1 diabetes. The submission is ...

A relatively quiet session on Wall Street ahead of Christmas saw stocks wavering near all-time highs as traders digested the gains of the past few sessions while parsing a reading on the jobs market.

Officials pledge ‘massive savings’ as companies agree to offer drugs at prices paid in other wealthy countries ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced ...

Saks Global, the company formed almost a year ago when Saks acquired Neiman Marcus Group for $2.7 billion, has had a rocky first year in business. Now, what will happen to Saks Global, and the many ...